MedTrace Logo

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

NCT02900664 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 283

Last updated 2022-03-29

No results posted yet for this study

Summary

The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Conditions

  • Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

Interventions

BIOLOGICAL

PDR001

Powder for solution for infusion

BIOLOGICAL

ACZ885

Solution for injection

BIOLOGICAL

CJM112

Solution for infusion

DRUG

TMT212

Tablets

DRUG

EGF816

Tablets

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-23
Primary Completion
2021-03-17
Completion
2021-03-17
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • France
  • Israel
  • Italy
  • Singapore
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02900664 on ClinicalTrials.gov